Alexander Filimonov

List of Publications by Year
in descending order

19	49	2258059 3	1872680 6
papers	citations	h-index	g-index

23	23	23	19
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Model of mammalian cell reproductive death I. Basic assumptions and general equations. Radiation and Environmental Biophysics, 1993, 32, 285-294.	1.4	9
2	Radioprotective Activity of the Nitric Oxide Synthase Inhibitor T1023. Toxicological and Biochemical Properties, Cardiovascular and Radioprotective Effects. Radiation Research, 2020, 194, 532-543.	1.5	8
3	Model of mammalian cell reproductive death II. Comparison with experimental data and discussion. Radiation and Environmental Biophysics, 1993, 32, 295-310.	1.4	4
4	Vasopressor Properties of Nitric Oxide Synthase Inhibitor T1059. Part I: Synthesis, Toxicity, NOS-Inhibition Activity, and Hemodynamic Effects Under Normotensive Conditions. Pharmaceutical Chemistry Journal, 2018, 52, 294-298.	0.8	3
5	Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bulletin of Experimental Biology and Medicine, 2019, 168, 92-94.	0.8	3
6	First Polynuclear Palladium Compounds [(C5H12NO)(PdCl3)]n and [(C10H16NO)2(Pd2Cl6)] with High Antitumor and Radioprotective Activity. Russian Journal of Coordination Chemistry/Koordinatsionnaya Khimiya, 2020, 46, 339-349.	1.0	3
7	The Ability of the Nitric Oxide Synthases Inhibitor T1023 to Selectively Protect the Non-Malignant Tissues. International Journal of Molecular Sciences, 2021, 22, 9340.	4.1	3
8	The influence of nitric oxide synthases inhibitor Ð¢1023 on the development of radiation pneumofibrosis in rats. RadiacionnaÃ¢ Gigiena, 2020, 13, 60-67.	0.7	3
9	Vasopressor Properties of No Synthase Inhibitor T1059. Part II. Hemodynamic Effects on Hypovolemic Disorders. Pharmaceutical Chemistry Journal, 2020, 53, 1113-1117.	0.8	2
10	Lactatemia as a possible pharmacological marker of NOS-inhibitor T1023 induced radioresistance. Radiation and Risk, 2020, 29, 45-56.	0.2	2
11	Combination of NOS- and PDK-Inhibitory Activity: Possible Way to Enhance Antitumor Effects. International Journal of Molecular Sciences, 2022, 23, 730.	4.1	2
12	Estimation of antitumor activity of compound T1097 - NOS inhibitor and glycolysis inhibitor - on experimental Erlich carcinoma in vivo. Journal of Physics: Conference Series, 2020, 1701, 012019.	0.4	1
13	Influence of the type of salt-forming acids on the antiradiation activity of T1023 analogs â€“ salts of N-isobutanoyl-S-isopropylisothiourea. RadiacionnaÃ¢ Gigiena, 2021, 14, 68-74.	0.7	1
14	The radioprotective effects of nitric oxide synthase inhibitor T1023 on normal and malignant tissues. Radiation and Risk, 2018, 27, 155-169.	0.2	1
15	Study of the ability of a new nitric oxide synthase inhibitor INOS1 to selectively protect the normal tissue in the Ehrlich carcinoma radiotherapy model. Radiation and Risk, 2018, 27, 37-45.	0.2	1
16	1-Isobutanoil-2-isopropylisothiourea Phosphate, T1082: A Safe and Effective Prevention of Radiotherapy Complications in Oncology. International Journal of Molecular Sciences, 2022, 23, 2697.	4.1	1
17	Mathematical modeling of the radiobiological effects of irradiation with stationary and pulsed neutron radiation. Atomic Energy, 1998, 85, 818-823.	0.4	0
18	Involvement of Recovery Processes in the Effects of Radioprotectors at the Cellular and Organismal Levels. Biology Bulletin, 2019, 46, 1619-1624.	0.5	0

#	Article	IF	Citations
19	Feasibility of nitric oxide synthesis inhibitor for the treatment of combined radiation injuries. Journal of Physics: Conference Series, 2020, 1701, 012015.	0.4	0